President Trump's Major Marijuana Move: What It Means for Canopy Growth, Green Thumb, and Tilray

President Trump's executive order to reschedule medical marijuana from Schedule I to Schedule III provides limited benefits to major cannabis companies. While the rescheduling eliminates IRS Section 280E tax restrictions for medical marijuana businesses, it only applies to medical products, not the larger recreational market. Canopy Growth, Tilray, and Green Thumb Industries face minimal direct impact due to their business structures and market focus, though the change creates new regulatory compliance burdens.